And Gilead cannot hit their numbers with much more price cutting. they have to make it up in volume. They and ABBV are at around $50K per treatment, as you say, coates, if someone comes along with a 6 or even 8 week treatment at 40-50k it instantly will take market share. Gilead does not want to participate in a race to the bottom in price - HCV is the only reason their revenues doubled - and they want to keep it that way. Once there is a completely dominant player, like Gilead with a 4 week cure (thanks to ACHN), it is conceivable that the price may actually start to climb again.
1H 2015 3422 + 3102 doublet for treatment naïve gen 1 for durations of 6, 8, 12 weeks. SVR4 2H 2015.
Q1 2015 POC for 3422 genotypes 2 and 3,. Results Q2 2015
1H 2015 sofo + 30102 + sovaprevir duration 4 weeks. SVR4 Results 2H 2015.
Q4 2015 pharmacokinetic and viral kinetic study 3422 + 3102 + sovaprevir treatment naïve gen 1
Q4 2015 Nominate a novel orally-administered complement factor D inhibitor and advance into a phase I clinical trial.
blueberry I think I'm going to start calling you rain man.
Lille (France), Boston (Massachusetts, United States), December 1st, 2014 – GENFIT (Euronext: GNFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of developing therapeutic and diagnostic solutions in metabolic and inflammatory diseases, that notably affect the liver or the gastrointestinal system, today announces that, in keeping with the scheduled agenda, all the patients of the GOLDEN-505 study (GFT505-212-7) have completed the one-year treatment period.
A total of 351 patients were screened according to the inclusion and exclusion criteria of the protocol, with the aim of recruiting 270 patients for the study.
Two hundred and seventy-five (275) patients that met all required criteria gave their consent, and were randomized to one of the three treatment groups of the study.
Two hundred and forty-one (241) patients completed the entire 12-month treatment period, and there were no safety issues during the study. It should be recalled that patient safety is ensured by an independent expert committee (the DSMB). The DSMB entirely reviewed the study safety data on two occasions during the treatment phase, and each time they gave a favorable opinion for the continuation of the study.
The drop-out rate during the treatment phase (34/275, i.e. 12%) is low for this type of study, and is two-fold lower than initially expected in the protocol (25%), thus illustrating the good tolerance of GFT505 and the patients’ willingness to accept the study constraints. In particular, the two liver biopsies, at beginning and end of treatment, did not lead to any consent withdrawal. This low drop-out rate increases the overall statistical power of the study.
I'll second that Larry. I find it amusing that many times earnings actually do move a development stage biotech company for an hour or a day - as if they matter a whit pre-approval. I think part of the action today is fallout from yesterday's downgrade, plus the notion that ABBV may now be off the table. I used to think PCYC was expensive at $130 (I sold then) - I had no idea someone would pay double that for half the revenue. In any case, ABBV still has about $40 billion left in its war chest, so a $3-5 billion acquisition of ACHN is not necessarily off the table at all. Meanwhile, Leerink and Brean Murray are both defending ACHN against the Barclay's downgrade. I expect Deutche to come out and say something positive as well if they haven't already.
mac, as you well know that you are prone to do you go in and out of coherence I mean your short positions, kinda like Bergy and God knows who else. Look, I think you're a fine human being on off hours (just guessing aimlessly here), but at the end of the day I want you to be asking for a loan from me and not the other way around. I'm pretty confident in my opinion, no matter what you call me x 100 or whatever. Capiche?
Mac, you're right. One hint of Tox and the price plummets. We all know there's always some risk in biotech investing. Right now, we think you're carrying the bigger risk being a short on this stock, even if you are holding open short positions for just a few days at a time.